M

MBX Biosciences Inc
NASDAQ:MBX

Watchlist Manager
MBX Biosciences Inc
NASDAQ:MBX
Watchlist
Price: 31.66 USD 3.06% Market Closed
Market Cap: 1.4B USD

Relative Value

There is not enough data to reliably calculate the relative value of MBX.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MBX Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.7
vs History
vs Industry
Median 3Y
-7.6
Median 5Y
-7.6
Industry
21.6
Forward
-11.9
vs History
vs Industry
Median 3Y
-8.7
Median 5Y
-8.7
Industry
16.9
vs History
vs Industry
Median 3Y
-8.6
Median 5Y
-8.6
Industry
22.9
vs History
11
vs Industry
Median 3Y
2.2
Median 5Y
2.2
Industry
2.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.6
vs History
vs Industry
Median 3Y
-3.9
Median 5Y
-3.9
Industry
13.4
Forward
-9.5
vs History
vs Industry
Median 3Y
-3.9
Median 5Y
-3.9
Industry
16.7
Forward
-9.2
vs History
vs Industry
Median 3Y
-4.6
Median 5Y
-4.6
Industry
16.1
vs History
vs Industry
Median 3Y
-4.6
Median 5Y
-4.6
Industry
18.9
vs History
44
vs Industry
Median 3Y
203.3
Median 5Y
203.3
Industry
2

Multiples Across Competitors

MBX Competitors Multiples
MBX Biosciences Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
MBX Biosciences Inc
NASDAQ:MBX
1.4B USD 0 -17.1 -10.8 -10.8
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.2 55.6 37.3 40
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
493.6B USD 5.4 19.7 16.1 20.9
CH
Roche Holding AG
SIX:ROG
271.9B CHF 4.4 28.8 12.3 14.3
UK
AstraZeneca PLC
LSE:AZN
220.4B GBP 5.1 31.4 108.7 159.2
US
Merck & Co Inc
NYSE:MRK
276.3B USD 4.3 14.5 10.3 12.2
CH
Novartis AG
SIX:NOVN
219.7B CHF 4.9 19.1 12.1 15.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.4 16.3 11.3 13.2
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
144.5B USD 2.3 14.7 7.5 10.2
P/E Multiple
Earnings Growth PEG
US
M
MBX Biosciences Inc
NASDAQ:MBX
Average P/E: 25
Negative Multiple: -17.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
55.6
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.7
29%
0.7
CH
Roche Holding AG
SIX:ROG
28.8
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.4
37%
0.8
US
Merck & Co Inc
NYSE:MRK
14.5
15%
1
CH
Novartis AG
SIX:NOVN
19.1
17%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
16.3
3%
5.4
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.7
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
M
MBX Biosciences Inc
NASDAQ:MBX
Average EV/EBITDA: 440.1
Negative Multiple: -10.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.3
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.1
9%
1.8
CH
Roche Holding AG
SIX:ROG
12.3
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
108.7
10%
10.9
US
Merck & Co Inc
NYSE:MRK
10.3
6%
1.7
CH
Novartis AG
SIX:NOVN
12.1
6%
2
DK
Novo Nordisk A/S
CSE:NOVO B
11.3
1%
11.3
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
M
MBX Biosciences Inc
NASDAQ:MBX
Average EV/EBIT: 1 883.7
Negative Multiple: -10.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
40
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.9
15%
1.4
CH
Roche Holding AG
SIX:ROG
14.3
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
159.2
23%
6.9
US
Merck & Co Inc
NYSE:MRK
12.2
8%
1.5
CH
Novartis AG
SIX:NOVN
15.6
12%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
13.2
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5